Human genetic evidence suggests that TG-lowering pharmacological agents that target ANGPTL3 and ANGPTL4 may prevent coronary artery disease (CAD), and ANGPTL4-targeting agents may also have beneficial effects for patients with type 2 diabetes (T2D).1,2 In addition, there appears to be no adverse association between genetic inhibition of ANGPTL4 in humans and the intra-abdominal complications seen in animal studies,1 or of human genetic inhibition and other diseases.2
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
